Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Bangwei Fang
Observed names:
Bangwei FANG,
Fang, Bangwei
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Shanghai Cancer Institute
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Shanghai Cancer Institute
ORCID:
0000-0002-3279-2140
Observed ORCID:
0000-0002-3279-2140
OpenAlex ID:
A5055978553
Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer
2024
·
Bangwei Fang
, Ying Lu
, et al.
·
Prostate Cancer and Prostatic Diseases
·
61
From biology to the clinic — exploring liver metastasis in prostate cancer
2024
·
Xudong Ni
, Yu Wei
, et al.
·
Nature Reviews Urology
·
25
Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients
2022
·
Bangwei Fang
, Yu Wei
, et al.
·
Cancer Immunology Immunotherapy
·
25
PDF
Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study
2025
·
Tingwei Zhang
, Beihe Wang
, et al.
·
Cell Reports Medicine
·
12
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity
2023
·
Yu Wei
, Tingwei Zhang
, et al.
·
Molecular Oncology
·
11
PDF
The Somatic Mutational Landscape of Mismatch Repair Deficient Prostate Cancer
2023
·
Bangwei Fang
, Yu Wei
, et al.
·
Journal of Clinical Medicine
·
8
PDF
Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with Metastatic Prostate Cancer
2023
·
Xudong Ni
, Junlong Wu
, et al.
·
European Urology Oncology
·
5
Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy
2024
·
Beihe Wang
, Jian Pan
, et al.
·
BMC Cancer
·
4
Development and validation of a nomogram (APGRC) to predict the presence of germline DNA damage repair pathogenic variants in Asian patients with prostate cancer
2023
·
Tingwei Zhang
, Yu Wei
, et al.
·
Clinical and Translational Medicine
·
4
EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer
2026
·
Bangwei Fang
, Xiaomeng Li
, et al.
·
Journal of Clinical Investigation
·
3
PDF
Mismatch repair gene germline mutations in patients with prostate cancer
2023
·
Bangwei FANG
, Yu WEI
, et al.
·
Journal of Zhejiang University (Medical Sciences)
·
3
PDF
Predicting pathogenic DNA damage repair gene mutations in prostate cancer patients: a multi-center magnetic resonance imaging radiomics study
2025
·
Yuntian Chen
, Jinge Zhao
, et al.
·
Quantitative Imaging in Medicine and Surgery
·
2
Applying prediction models in clinical practice: the importance of fine details
2023
·
Bangwei Fang
, Yao Zhu
·
Prostate Cancer and Prostatic Diseases
·
1
PDF
Expression of Concern for EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer
2026
·
Bangwei Fang
, Xiaomeng Li
, et al.
·
Journal of Clinical Investigation
Show more works
View as search
Works count:
16
Citation count:
164
H-index:
6
I10-index:
5
Year
Topic
Type